Desmopressin in Mild Hemophilia A: Indications, Limitations, Efficacy, and Safety

 

 Buy Article Permissions and Reprints

ABSTRACT

Replacement therapy with blood products has long been the only available therapeutic option for patients with bleeding disorders. Plasma-derived cryoprecipitate and factor (F) VIII concentrates, which have been used for hemophilia A patients, involve the risk of transmitting blood-borne diseases. Both plasma-derived and recombinant FVIII concentrates are expensive, and there is a global shortage. The synthetic vasopressin analogue desmopressin acetate (1-deamino-[8-D-arginine]-vasopressin, DDAVP) increases plasma concentrations of coagulation FVIII and von Willebrand factor (vWF) two fold to six fold through endogenous release. The drug is an attractive therapeutic alternative because it carries no risk of transmission of infectious diseases. Desmopressin is today a widely used hemostatic agent not only in patients with mild hemophilia A or von Willebrand disease (vWD) but also in those with congenital or acquired platelet dysfunction. There is a long clinical experience with the drug because it has been used for prevention of bleedings in connection with invasive procedures and for treatment of bleedings since the mid-1970s. Not all hemophilia A patients can be treated. The clinical usefulness depends on the postdesmopressin plasma concentration of FVIII, which in turn depends on the patient's basal FVIII level. Therefore, a test dose is recommended in candidate patients. In general, only the mildest hemophilia A patients respond sufficiently. Optimal hemostatic effect is achieved with a dosage of 0.3 μg/kg given intravenously. An intranasal desmopressin spray is suitable for the home treatment.

REFERENCES

• 1 Cash J D, Gader A MA, Da Costa J. The release of plasminogen activator and factor VIII by LVP, AVP, DDAVP, AT III and OT in man.  Br J Haematol . 1974;  27 363-364
  PubMedGoogle Scholar
• 2 Mannucci P M, Åberg M, Nilsson I M, Robertsson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs.  Br J Haematol . 1975;  30 81-93
  CrossrefPubMedGoogle Scholar
• 3 Mannucci P M, Ruggeri Z M, Pareti F I, Capitanio A. 1-deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of hemophilia and von Willebrand disease.  Lancet . 1977;  1 869-872
  PubMedGoogle Scholar
• 4 Warrier I, Lusher J M. DDAVP-a useful alternative to blood components in moderate hemophilia A and von Willebrand's disease.  J Pediatr . 1983;  102 228
  CrossrefPubMedGoogle Scholar
• 5 Mariani G, Ciavarella N, Mazzucconi M G. et al . Evaluation of the effectiveness of DDAVP in surgery and bleeding episodes in hemophilia and von Willebrand disease. A study of 43 patients.  Clin Lab Haematol . 1984;  6 229-238
  PubMedGoogle Scholar
• 6 de la Fuente B, Kasper C K, Rickles F R, Hoyer L W. Response of patients with mild and moderate hemophilia A and von Willebrand disease to treatment with desmopressin.  Ann Intern Med . 1985;  103 6-14
  CrossrefPubMedGoogle Scholar
• 7 Mannucci P M, Canciani M T, Rota L, Donovan B S. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects, and patients with hemophilia A and von Willebrand disease.  Br J Haematol . 1981;  47 283-293
  PubMedGoogle Scholar
• 8 Nilsson I M, Lethagen S. Current status of DDAVP formulations and their use. In: Lusher JM, Kessler CM, eds. Hemophilia and von Willebrand Disease in the 1990s Amsterdam: Elsevier Science Publishers B.V. 1991: 443-453
  Google Scholar
• 9 Mannucci P M, Vicente V, Alberca I. et al . Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses.  Thromb Haemost . 1987;  58 1037-1039
  PubMedGoogle Scholar
• 10 Ghirardini A, Mariani G, Iacopino G. et al . Concentrated DDAVP: further improvement in the management of mild factor VIII deficiencies.  Thromb Haemost . 1987;  58 896-898
  PubMedGoogle Scholar
• 11 Rose E H, Aledort L M. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease.  Ann Intern Med . 1991;  114 563-568
  CrossrefPubMedGoogle Scholar
• 12 Lethagen S, Harris A S, Sjörin E, Nilsson I M. Intranasal and intravenous administration of desmopressin: effect on f VIII/ VWF, pharmacokinetics and reproducibility.  Thromb Haemost . 1987;  58 1033-1036
  PubMedGoogle Scholar
• 13 Lethagen S, Egervall K, Berntorp E, Bengtsson B. The administration of desmopressin by nasal spray. A dose determining study in patients with mild haemophilia A and von Willebrand's disease.  Haemophilia . 1995;  1 97-102
  PubMedGoogle Scholar
• 14 Lethagen S, Ragnarson-Tenvall G. Self-treatment with desmopressin intranasal spray in patients with bleeding disorders. Effect on bleeding symptoms and socio-economic factors.  Ann Hematol . 1993;  66 257-260
  CrossrefPubMedGoogle Scholar
• 15 Nilsson I M, Lethagen S. Current status of DDAVP formulations and their use. In: Lusher JM, Kessler CM, eds. Hemophilia and von Willebrand Disease in the 1990s Amsterdam: Elsevier Science Publishers B.V. 1991: 443-453
  Google Scholar
• 16 Mudad R, Kane W H. DDAVP in acquired hemophilia A: case report and review of the literature.  Am J Hematol . 1993;  43 295-299
  CrossrefPubMedGoogle Scholar
• 17 Nilsson I M, Felding P, Timberg L, Jonsson S, Harris A S. Clinical experience with DDAVP. In: Ciavarella NL, Ruggeri Z, Zimmerman TS, eds. Factor VIII/von Willebrand Factor. Biological and Clinical Advances Proceedings of Bari Int Conference. Milano: Wichtig Editore 1986: 63-80
  Google Scholar
• 18 Lowe G, Pettigrew A, Middleton S, Forbes C D, Prentice C RM. DDAVP in hemophilia.  Lancet . 1977;  2 614-615
  PubMedGoogle Scholar
• 19 Theiss W, Schmidt G. DDAVP and von Willebrand disease: repeated administration and the behaviour of the bleeding time.  Thromb Res . 1978;  13 1119-1123
  CrossrefPubMedGoogle Scholar
• 20 Mannucci P M, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP).  Br J Haematol . 1992;  82 87-93
  CrossrefPubMedGoogle Scholar
• 21 Mannucci P M. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders.  Blood . 1988;  72 1449-1455
  PubMedGoogle Scholar
• 22 Koskimies O, Pylkkänen J, Vilska J. Water intoxication in infants caused by the urine concentration test with vasopressin analogue (DDAVP).  Acta Paediatr Scand . 1984;  73 131-132
  PubMedGoogle Scholar
• 23 Sheperd L L, Hutchinson R J, Worden E K, Koopman C F, Coran A. Hyponatremia and seizures after intravenous administration of desmopressin acetate for surgical hemostasis.  J Pediatr . 1989;  114 470-472
  PubMedGoogle Scholar
• 24 Weinstein R E, Bona R D, Altman A J. et al . Severe hyponatremia after repeated intravenous administration of desmopressin.  Am J Hematol . 1989;  32 258-261
  CrossrefPubMedGoogle Scholar
• 25 Smith T J, Gill J C, Ambruso D R, Hathaway W E. Hyponatremia and seizures in young children given DDAVP.  Am J Hematol . 1989;  31 199-202
  CrossrefPubMedGoogle Scholar
• 26 Salvatoni A, Maghnie M, Lorini R, Marni E. Hyponatremia and seizures during desmopressin acetate treatment in hypothyroidism.  J Pediatr . 1990;  116 835-836
  PubMedGoogle Scholar
• 27 Binch L JC, Jacobsen M B. Hyponatremi ved behandling av von Willebrands sykdom.  Tidsskr Nor Laegeforen . 1992;  112 3670-3671
  PubMedGoogle Scholar
• 28 Beach P S, Beach R E, Smith L R. Hyponatremic seizures in a child treated with desmopressin to control enuresis. A rationale approach to fluid intake.  Clin Pediatr (Phila) . 1992;  31 566-569
  PubMedGoogle Scholar
• 29 Yaouyanc G, Jonville A P, Yaouyanc-Lapalle H. et al . Seizure with hyponatremia in a child prescribed desmopressin for nocturnal enuresis.  J Toxicol Clin Toxicol . 1992;  30 637-641
  PubMedGoogle Scholar
• 30 Humphries K E, Siragy H. Significant hyponatremia following DDAVP administration in a healthy adult.  Am J Hematol . 1993;  44 12-15
  PubMedGoogle Scholar
• 31 Lethagen S, Frick K, Sterner G. Antidiuretic effect of desmopressin given in hemostatic dosage to healthy volunteers.  Am J Hematol . 1998;  57 153-159
  CrossrefPubMedGoogle Scholar
• 32 O'Brien J R, Green P J, Salmon G. et al . Desmopressin and myocardial infarction (Letter).  Lancet . 1989;  664
  PubMedGoogle Scholar
• 33 van Dantzig M J, Duren D R, ten Cate W J. Desmopressin and myocardial infarction (Letter).  Lancet . 1989;  664
  PubMedGoogle Scholar
• 34 Bond L, Bevan D U. Myocardial infarction in a patient with hemophilia treated with DDAVP (Letter).  N Engl J Med . 1988;  318 121
  PubMedGoogle Scholar
• 35 Mannucci P M, Lusher J M. Desmopressin and thrombosis.  Lancet . 1989;  ii 675-676
  PubMedGoogle Scholar
• 36 Mannucci P M, Carlsson S, Harris A S. Desmopressin, surgery and thrombosis.  Thromb Haemost . 1994;  71 154-155
  PubMedGoogle Scholar